Skip to main content

Improved Patient Care by Combinatorial Treatment

Project description

New target in combinatorial breast cancer treatment

Targeted precision medicine in combination with companion diagnostics (a diagnostic test to determine the applicability of the therapeutic drug to a specific person) represents an attractive option for effective patient care. Recent advances in breast cancer treatment using a combination of targets are at the forefront of this development. The recently discovered Nudix-linked to moiety X-5 enzyme (NUDIX5) plays a role in adenosine triphosphate generation in the nucleus. Overexpression of the NUDIX5 in breast and other types of cancer has been associated with a poor prognosis and increased risk of recurrence and metastasis. The EU-funded IMPACCT project proposes to determine if the developed NUDIX5 inhibitors, in combination with companion diagnostics, can be used as a targeted treatment in breast cancer patients.

Host institution

FUNDACIO CENTRE DE REGULACIO GENOMICA
Net EU contribution
€ 145 000,00
Address
Carrer Doctor Aiguader 88
08003 Barcelona
Spain

See on map

Region
Este Cataluña Barcelona
Activity type
Research Organisations
Other funding
€ 145 000,00

Beneficiaries (1)

FUNDACIO CENTRE DE REGULACIO GENOMICA
Spain
Net EU contribution
€ 145 000,00
Address
Carrer Doctor Aiguader 88
08003 Barcelona

See on map

Region
Este Cataluña Barcelona
Activity type
Research Organisations
Other funding
€ 145 000,00